Company Profilelipocureis Start Up That Focuses On Development Of Nano Drugs Based On Liposomeslipocureutilizes Thevast Experiencegained By Professor Yechezkel Barenholzoneof Themajor Inventors And Developers Of Thefirst Fda Approved Nano Drugdoxila Doxil Is An Anti Cancer Drug Considered As Oneof Thegold Standards Of Nano Drug Delivery Systemsdds Thetechnological And Biological Knowledgegained During Doxil Development Has Led To Thedevelopment Of Anti Cancer Nano Drugs With Improved Efficacy And Reduced Toxicity Compared To Doxilas Well As To Thedevelopment Of Anti Inflammatory Nano Drugsthelipocurepipelineincludes Projects Closeto Clinical Trialsand Other Projects In Preclinical Stages All Thedrugs Developed By Lipocuresharetheprinciples Of Better Control Over Pharmacokinetics And Bio Distributionpassivetargeting At Thediseasesiteand Controlled Drug Releaseall Activepharmaceuticals Used Aregenerictheoverall Superiority Of Lipocures Novel Drugs Stems From Theaboveadvantagesenabling Achieving An Improved Therapeutic Index By Improving Efficacy And Reducing Toxicity Technology Description Utilizing Thegroup S Expertisein Liposomes And Nanotechnologylipocurehas Developed A Pipelineof Products Lc100 Ae Liposomal Doxorubicin Nano Drug With Greater Efficacy And Reduced Sideeffectsin Particularreduced Hand And Foot Syndromein Comparison To Current Pegylated Liposomal Doxorubicin Lc200 Ae Long Circulating Inflammation Targeted Steroidal Nano Liposomal Drug With Improved Efficacy Profilein Preclinical Animal Models To Beused As Anti Inflammatory And Anti Cancer Drug Lc400 Ae Ulalaultra Long Acting Local Anestheticlargemulti Vesicular Liposomehydrogel Loaded With Bupivacainewith Slow Releaseand Improved Safety And Efficacy Demonstrated In First In Human Clinical Study Phasei
